APA (7th ed.) Citation

JM, W., P, G., N, G., C, K., M, S., U, H., . . . T, R. (2026). Non-ICANS neurotoxicity after BCMA-directed CAR-T therapy: Clinical spectrum, outcomes, and a framework for neurology-oncology co-management. HemaSphere, 10(6), e70404. https://doi.org/10.1002/hem3.70404

Chicago Style (17th ed.) Citation

JM, Werner, et al. "Non-ICANS Neurotoxicity After BCMA-directed CAR-T Therapy: Clinical Spectrum, Outcomes, and a Framework for Neurology-oncology Co-management." HemaSphere 10, no. 6 (2026): e70404. https://doi.org/10.1002/hem3.70404.

MLA (9th ed.) Citation

JM, Werner, et al. "Non-ICANS Neurotoxicity After BCMA-directed CAR-T Therapy: Clinical Spectrum, Outcomes, and a Framework for Neurology-oncology Co-management." HemaSphere, vol. 10, no. 6, 2026, p. e70404, https://doi.org/10.1002/hem3.70404.